Epigenetic Shenanigans—In AD, Chromatin Opens Up in Blood Immune Cells
In CD8+ T cells and monocytes, DNA was more accessible in people with AD and even more so in ApoE4 carriers.
6471 RESULTS
Sort By:
In CD8+ T cells and monocytes, DNA was more accessible in people with AD and even more so in ApoE4 carriers.
£50 million in funding will expand trial access, increase recruitment, streamline study processes, and train staff over the next five years.
In mice, these Aβ fibrils avoid riling microglia and astrocytes. They also evade both PiB and lecanemab.
Using live imaging in mice, scientists found that tracers and immune cells move between brain and dura through gaps in the arachnoid mater around veins.
With newly available fluid biomarkers that detect α-synuclein pathology in the brain, researchers articulate ways to classify the disease based on its biology.
ApoE2 reported as raising risk for progressive supranuclear palsy, a rare tauopathy.
A Rand report concludes that using blood-based biomarkers and cognitive tests in primary care would halve wait times for new disease-modifying therapies.
The company announced it would halt its post-market trial and stop selling the drug; the rights to it now revert to Swiss company Neurimmune.
Among 1,092 people with PCA, symptoms started around age 60, and 94 percent had amyloid plaques or neurofibrillary tangles.
The α-helical chains of two ApoEs wrap around lipoprotein discs. They circle in opposite directions.
Eight adults who, as children, had received growth hormone from cadavers developed cognitive problems and/or AD-like pathology in midlife.
Risk variant promotes TMEM106b fibrillization; protective variant discourages it.
The patient, an APOE4 homozygote with severe cerebral amyloid angiopathy, developed vascular inflammation and bleeding throughout her brain.
With several thousand people across the U.S. on the drug, wait times are long, and clinics are hiring. How to meet growing demand?
Scientists around the globe are studying how best to deploy Alzheimer's plasma tests in the real world. Their focus: primary care.